Polycystic Ovary Syndrome: The Daily PANCE Blueprint
A 24-year-old woman has had only four or five periods a year since menarche. Over the past three years she has gained 30 pounds and developed coarse dark hair on her chin and upper lip along with persistent acne. Her BMI is 32, and there is velvety hyperpigmented skin at the nape of her neck and in both axillae. A pregnancy test is negative, and TSH, prolactin, and 17-hydroxyprogesterone are all normal. Total testosterone is mildly elevated. Pelvic ultrasound shows multiple small peripheral follicles in both ovaries. Which of the following is the most likely diagnosis?
A. Congenital adrenal hyperplasia
B. Cushing syndrome
C. Polycystic ovary syndrome
D. Androgen-secreting ovarian tumor
E. Primary hypothyroidism
Answer and topic summary
The answer is C. Polycystic ovary syndrome
Oligomenorrhea plus clinical and biochemical hyperandrogenism plus polycystic-appearing ovaries is polycystic ovary syndrome — and by the Rotterdam criteria she needs only two of those three, after other causes are excluded. That exclusion step is what the normal pregnancy test, TSH, prolactin, and 17-hydroxyprogesterone are doing in the stem; they are not filler. The velvety hyperpigmentation is acanthosis nigricans, the visible signature of insulin resistance, which sits at the center of the syndrome: hyperinsulinemia drives ovarian theca cells to overproduce androgens and lowers sex hormone-binding globulin, raising free testosterone further, while disordered gonadotropin pulsing raises the LH:FSH ratio and stalls follicles before ovulation. That is why the ultrasound shows many small peripheral follicles rather than true “cysts” — and why ultrasound is supportive, not required. And that is exactly why the name changed: in May 2026 an international consensus of more than 50 professional and patient organizations renamed this condition polyendocrine metabolic ovarian syndrome (PMOS), because naming an endocrine-metabolic disease after an ovarian imaging finding pointed clinicians at the ultrasound instead of the insulin resistance that actually drives the morbidity. The Rotterdam criteria are unchanged, and a three-year transition runs through the 2028 International Guideline update — so expect PCOS on your exam and in the NCCPA blueprint for now, and PMOS increasingly in the literature and on rotations. Management follows what she wants. Weight loss and exercise are first-line and can restore ovulation on their own. For cycle control and hirsutism, use a combined oral contraceptive, adding spironolactone for hair; for fertility, letrozole is now first-line ovulation induction, ahead of clomiphene; and metformin helps the metabolic picture. Do not forget the long game: screen for type 2 diabetes, dyslipidemia, obstructive sleep apnea, and depression, and remember that chronic unopposed estrogen from anovulation raises the risk of endometrial hyperplasia and carcinoma, so these patients need scheduled withdrawal bleeding or progestin protection. The distractors: nonclassic congenital adrenal hyperplasia is excluded by the normal 17-hydroxyprogesterone; Cushing syndrome adds striae, proximal weakness, a dorsocervical fat pad, and easy bruising; an androgen-secreting tumor produces rapid virilization with a markedly elevated testosterone rather than a mild rise over years; and hypothyroidism is excluded by the normal TSH.
View blueprint lesson
Smarty PANCE Content Blueprint Review:
Covered under ⇒ PANCE Blueprint Reproductive ⇒ ⇒
